A Phase 1, Open-label, Drug-Drug Interaction Study to Assess the Steady State Pharmacokinetics of N91115 Alone and in the Presence of Multiple Dose Administration of Rifampin in Healthy Adult Subjects (SNO-5)

Trial Profile

A Phase 1, Open-label, Drug-Drug Interaction Study to Assess the Steady State Pharmacokinetics of N91115 Alone and in the Presence of Multiple Dose Administration of Rifampin in Healthy Adult Subjects (SNO-5)

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Cavosonstat (Primary) ; Rifampicin
  • Indications Cystic fibrosis
  • Focus Pharmacokinetics
  • Acronyms SNO-5
  • Sponsors Nivalis Therapeutics
  • Most Recent Events

    • 12 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 04 Jan 2016 Planned End Date changed from 1 Nov 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov.
    • 21 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top